|
Canada-0-SLATE Azienda Directories
|
Azienda News:
- U. S. FDA Approves Broad New Labels for NEXLETOL® and NEXLIZET . . .
U S FDA Approves Broad New Labels for NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use
- label - accessdata. fda. gov
Bempedoic acid, a component of NEXLIZET, is indicated: • to reduce the risk of major adverse cardiovascular events (cardiovascular death, myocardial infarction, stroke, or coronary revascularization) in adults at increased risk for these events who are unable to take recommended statin therapy (including those not taking a statin) 2
- NEXLIZET® NEXLETOL® CLEAR Outcomes Trial Information
NEXLIZET and NEXLETOL are indicated: The bempedoic acid component of NEXLIZET and NEXLETOL is indicated to reduce the risk of myocardial infarction and coronary revascularization in adults who are unable to take recommended statin therapy (including those not taking a statin) with: established cardiovascular disease (CVD), or at high risk for a CVD event but without established CVD As an
- Bempedoic Acid: A Review in Cardiovascular Risk Reduction in . . .
Abstract Oral bempedoic acid (NEXLETOL ® in the USA; Nilemdo ® in the EU) and the fixed dose combination (FDC) of bempedoic acid ezetimibe (NEXLIZET ® in the USA; Nustendi ® in the EU) are approved to reduce cardiovascular (CV) risk in statin-intolerant patients who are at high risk for, or have, CV disease A first-in-class therapy, bempedoic acid inhibits the adenosine triphosphate
- NEXLIZET- bempedoic acid and ezetimibe tablet, film coated
NEXLIZET is indicated as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease who require additional lowering of LDL-C Limitations of Use
- U. S. FDA Approves Broad New Labels for NEXLETOL® and NEXLIZET . . .
ANN ARBOR, Mich , March 22, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the United States Food and Drug Administration (FDA) has approved broad new label expansions for NEXLETOL ® (bempedoic acid) Tablets and NEXLIZET ® (bempedoic acid and ezetimibe) Tablets based on positive CLEAR Outcomes data that include indications for cardiovascular risk reduction and expanded
- FDA Expands Labels for Nexletol, Nexlizet to Prevent Heart . . .
U S FDA approves broad new labels for Nexletol and Nexlizet to prevent heart attacks and cardiovascular procedures in both primary and secondary prevention patients, regardless of statin use
- NEXLIZET® to Prevent Heart Attacks and Cardiovascular . . .
Esperion announced that the United States Food and Drug Administration (FDA) has approved broad new label expansions for NEXLETOL® (bempedoic acid) Tablets and NEXLIZET® (bempedoic acid and ezetimibe) Tablets based on positive CLEAR Outcomes data that include indications for cardiovascular risk reduction and expanded LDL-C lowering in both primary and secondary prevention patients
- U. S. FDA Approves Broad New Labels for Esperion . . . - BioSpace
U S FDA approves broad new labels for NEXLETOL® (bempedoic acid) Tablets and NEXLIZET® (bempedoic acid and ezetimibe) Tablets to prevent heart attacks and cardiovascular procedures in both primary and secondary prevention patients, regardless of statin use
- Esperion’s Nexletol and Nexlizet Receive FDA Approval for . . .
The United States approvals of Nexlizet and Nexletol for cardiovascular risk reduction and LDL-C lowering were based on data generated from the CLEAR Outcomes trial assessing the effect of Nexletol on cardiovascular outcomes in approximately 14,000 patients with or at high risk of cardiovascular disease (CVD)
|
|